NCT04354129View on ClinicalTrials.gov

Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

Active, not recruitingOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Primary Immune Deficiency DisorderSecondary Immune Deficiency
Interventions
DRUG

Cutaquig®

Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.

Trial Locations (1)

T6G 2R3

University of Alberta, Edmonton

Sponsors

Collaborators (1)

Octapharma
All Listed Sponsors
collaborator

Octapharma

INDUSTRY

lead

University of Alberta

OTHER

NCT04354129 - Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. | Biotech Hunter | Biotech Hunter